



**TERMIS – EU SYMPOSIUM SUBMISSION FORM**

<b>Title:</b>	COMMERCIALIZING CELL THERAPIES. TRAGEDY, TUMULT AND TRIUMPH	
	<b>Name</b>	<b>Affiliation</b>
<b>Chair:</b>	Brian Newsom	Life Technologies
<b>Co-Chairs:</b>		
<b>Keynote Speaker *:</b>	Gil Beyen Eduardo Bravo	Tigenix Cellerix
<b>Organizers:</b>	Brian Newsom	Life Technologies
<b>Synopsis:</b> Please provide a brief synopsis of the proposed symposium (up to 600 words). Please use allocated space below.		
<p>Taking a cell therapy from development to commercialization has proven to be a rocky road. Along this road we see many that have fallen to the wayside and there are many more that will no doubt end up with that fate. There are some, however, that have overcome the hurdles (the regulation, the funding, the clinical proof) to bring their therapies to late stage trials and commercialization. We will hear of the trials and tribulations of those that have paved the way to success in the area of Tissue Engineering and from those on the brink of success.</p> <p>Bringing a cell therapy to the market takes a lot more than interesting or even useful science. It takes a lot of dedicated people, exceptional funding (and therefore fundraising skills), good clinical practice, attention to detail in manufacturing, quality and logistics &amp; and strong case for being able to generate revenues at the end of a 10+ year development cycle.</p> <p>To date only 4 companies have managed to finish this trek, and only one under the new European ATMPs. We will hear from this company as well as another company that may join them as the second member of this elite group to find out how they achieved this feat and what wisdom they can pass along to those currently developing cellular therapies.</p>		
<b>Symposium Keywords:</b>	Commercialization, Industry	

**\*The Keynote Speaker needs to be confirmed at the time of the proposal**